Elizabeth Cunningham

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 501 citations · Full text

Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

Georgina V. Long, Jeffrey S. Weber, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2016 · 284 citations

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i>^V600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Douglas B. Johnson, Keith T. Flaherty, Jeffrey S. Weber et al. · Journal of Clinical Oncology · 2014 · 208 citations · Full text

Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer

Tohru Yamada, Masatoshi Goto, Vasu Punj et al. · Proceedings of the National Academy of Sciences · 2002 · 185 citations · Full text

Apoptosis, Pathology, Cell Death +17

Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer

Vasu Punj, Suchita Bhattacharyya, Djenann Saint‐Dic et al. · Oncogene · 2004 · 164 citations

Breast Oncology, Bacterial Cupredoxin Azurin, Medicine +9